GeneralConnection.com ➔ Dictionary
Dictionary Search

factor ix

Synonyms

Noun

1. Christmas factor

2. factor IX, coagulation factor, clotting factor

Usage
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - NEJM
Advances in hemophilia, sickle cell disease, and thalassemia - Penn Medicine
AAV gene therapy shows durable benefit in hemophilia B - 2 Minute Medicine
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - EMJ
Systemic lupus erythematosus caused acquired hemophilia B without evidence of factor IX inhibitors - Wiley Online Library
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Hemophilia B Gene Therapy Continues to Reduce Bleeding - Medscape
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
Explainer 2025 Why Is Hemophilia B Called Christmas Disease - Global Biotechnology Company
Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting - Biogen
Gene Therapy Maintains Efficacy in Hemophilia B Out to 5 Years - MedPage Today
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
How Gene Therapy Is Transforming Hemophilia B Treatment - Docwire News
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report - Wiley
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B - NEJM
How durable is gene therapy for haemophilia B? - Nature
One dose of gene therapy gives years of relief from blood disorder - Nature
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - NEJM
Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later - MedPage Today
Gene Therapy Cuts Bleeding and Medicine for Hemophilia B Patients for Over a Decade - Managed Healthcare Executive
Use of anti-haemophilia medicine suspended across Punjab after reports of adverse reactions - The Tribune
Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product - Nature
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - NEJM
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B - NEJM
What is Hemophilia B? - Global Biotechnology Company
Systemic delivery of factor IX messenger RNA for protein replacement therapy - PNAS
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - NEJM
Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies - Nature
Haemophilia gene therapy patients thriving over a decade after treatment | UCL News - UCL - UCL | University College London
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - NEJM
Plasma factor IX: The tip of the iceberg? - Sidonio - 2021 - Haemophilia - Wiley Online Library
This gene therapy costs $5 million a dose. Is it worth the price? - SMH.com.au
Multiyear Follow-up Study Shows Positive Results for Hemophilia B Gene Therapy - Managed Healthcare Executive
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence - Nature
A novel snake venom C-type lectin-like protein modulates blood coagulation by targeting von Willebrand factor and coagulation factor IX - Nature
Etranacogene Dezaparvovec Displays Superiority to Factor IX Prophylaxis for Hemophilia B in HOPE-B Trial Data - CGTLive®
First gene therapy to treat haemophilia B - European Medicines Agency (EMA)
HTC Population Profile Patient Characteristics - Centers for Disease Control and Prevention | CDC (.gov)
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab - American Heart Association Journals
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space - Wiley
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis - American Heart Association Journals
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial - Applied Clinical Trials Online
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - NEJM
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Wiley Online Library
Hemophilia B Durham: A Mutation in the First EGF-Like Domain of Factor IX That Is Characterized by Polymerase Chain Reaction - ScienceDirect.com
CDC Hemophilia Mutation Projects (CHAMP and CHBMP) - Centers for Disease Control and Prevention | CDC (.gov)
Krüppel-like factor 9 alleviates Alzheimer’s disease via IDE-mediated Aβ degradation - Nature
Association Between Hepatic Triglyceride Content and Coagulation Factors: - American Heart Association Journals
Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study - The Lancet
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B - Biogen
Factor Levels Lower Than 50% Associated With Postpartum Complications in Patients With Hemophilia - Hematology Advisor
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X - PNAS
UC San Diego Health First to Offer Novel Gene Therapy for Hemophilia B - UC San Diego Health
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI - PNAS
Gene therapy fails to induce sustained factor IX activity for patients with hemophilia B - Healio
Factor IX Deficiency and Prolonged Bleeding Time - NEJM
Pfizer: Beqvez Gene Therapy Decreases Bleeding Rates in Hemophilia B Patients - 2 Minute Medicine
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A - NEJM
A coagulation factor moonlights in the heart - Science | AAAS
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors - Nature
The Experience Factor: 9 activations which lit up summer travel retail - DFNI
High Adherence, Excellent Outcomes Seen With EHL Factor VIII and IX Concentrates in Hemophilia - Hematology Advisor
Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria - Nature
Glucocorticoids increase adiposity by stimulating Krüppel-like factor 9 expression in macrophages - Nature
Intellia opts out of hemophilia B gene editing work with Regeneron - Fierce Biotech
St. Jude's contribution to two new durable 'one-time' hemophilia drugs - St. Jude Children's Research Hospital
Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen - Wiley Online Library
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response - Nature
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - NEJM
Hemophilia B Gene Therapy Produces Durable Response for 90% of Participants - AJMC
Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A - Frontiers
Real-world outcomes with recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis: Longitudinal follow-up in a national adult cohort - Wiley Online Library
Emicizumab Prophylaxis in Hemophilia A with Inhibitors - NEJM
Gene Therapy for Hemophilia B Significantly Outperforms Factor IX Prophylaxis - MedPage Today
A genetic analysis of 23 Chinese patients with hemophilia B - Nature
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors - NEJM
Effective Blood Clotting Treatment:Pharmacogenomic Studies of ADAMTS13 - fda.gov
Hemophilia Gene Therapies Show Effectiveness and Safety in NEJM Reports - Inside Precision Medicine
Personal Story: Carrie - Centers for Disease Control and Prevention | CDC (.gov)
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
Hemophilia therapy: the future has begun - Haematologica
Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma - Nature
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity - Wiley Online Library
Is Hemophilia a Nosologic Entity? - ScienceDirect.com
Factor IX Deficiency and Prolonged Bleeding Time - NEJM
New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use - Biogen
The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A - NEJM
Single-dose gene therapy is potentially life-changing for adults with hemophilia B - Penn Medicine
Biogen Idec Receives Notification from FDA of PDUFA Date Extension for ALPROLIX™ - Biogen
Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk - Nature
Hemophilia B Gene Therapy Shows Promise in Clinical Trial - Genetic Engineering and Biotechnology News
Fidanacogene Elaparvovec Shows Strong Results in Open-Label Phase 3 Study - AJMC
Breaking ground in haemophilia B gene therapy: insights from the HOPE-B trial and beyond - The Lancet
Hemostasis — A Balancing Act - NEJM
Interferon Regulatory Factor 9 Structure and Regulation - Frontiers
Foreign Language Equivalents
Foreign Language Equivalents of 'factor ix'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
factor ux,   factpr ix,   afctor ix,   factor i,   factoor ix,   factir ix,   facor ix,   factor iix,   factorix,   favtor ix,   faxtor ix,   factor x,   factori x,   faactor ix,   factoe ix,   facto ix,   fator ix,   ffactor ix,   factor ix,   factorr ix,   facto rix,   factor xi,   factor ic,   fctor ix,   factor ox,   facror ix,   fcator ix,   facter ix,   fsctor ix,   factro ix,   gactor ix,   factor iz,   factot ix,   facttor ix,   factor ixx,   fatcor ix,   facctor ix,   facyor ix,   facotr ix,   factr ix,   actor ix,   dactor ix
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z